Medscape

Skin Problems Common at Insulin Pump Infusion Sites

Pump vs control sites had greater vessel density, fibrosis, fibrinogen, and inflammation including eosinophils, insulin-like-growth factor-1 (IGF-1), and transforming growth factor (TGF) β-3, as well ...
Nature

Continuous Insulin Infusion in Type 1 Diabetes

Continuous subcutaneous insulin infusion (CSII) has become an indispensable modality in the management of type 1 diabetes. This therapy employs an insulin pump to deliver both basal and bolus doses, ...
FierceBiotech

FDA gives Class I recall rating to insulin infusion sets used with Tandem pumps

The tubing used to subcutaneously deliver insulin from a Tandem Diabetes Care pump is among the latest devices to land in the FDA’s hot seat. Unomedical A/S began a recall of some of its VariSoft ...
Business Wire

Capillary Biomedical Receives FDA Approval to Begin Pivotal Trial of Its SteadiFlow Seven-Day-Wear Infusion Set Technology

IRVINE, Calif.--(BUSINESS WIRE)--Medical device developer Capillary Biomedical, Inc. (CapBio) has announced that it has received investigational device exemption (IDE) approval from the U.S. Food and ...
Monthly Prescribing Reference

FDA Approves Myxredlin, a Ready-to-Use Insulin for IV Infusion

The FDA has approved Myxredlin (Baxter), the first ready-to-use insulin for intravenous (IV) infusion for use in acute care settings under medical supervision. The Food and Drug Administration (FDA) ...
Medscape

Skin Problems Common at Insulin Pump Infusion Sites

Skin reactions at insulin pump infusion sites are common among people with type 1 diabetes who use the devices and can lead to delivery failure, new research suggests. Insulin pump use is increasingly ...